Genmab A/S GNMSF

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $3.72B · Filed Feb 17, 2026

Genmab A/S (GMAB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.7 billion and net income of $963.0 million. Free cash flow was $1.1 billion. As of Dec 31, 2025 it held $1.7 billion in cash and investments and $5.4 billion in total debt.

Revenue
$3.72B
Net income
$963.00M
Operating cash flow
$1.19B
Free cash flow
$1.15B
EPS
$15.37
Dividend per share
None
Shares outstanding
64.24M
-1.3% vs prior year
Net cash
$-3.71B
FY 2025
Operating margin
28.6%
FY 2025

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GMAB (Nasdaq), GNMSF (OTC)
Headquarters
1253 Copenhagen K, Denmark
SEC filer status
Large accelerated filer
SEC CIK
1434265

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$3.7B
Operating income
$1.1B
Net income
$963.0M
Diluted EPS
$15.37
Operating cash flow
$1.2B
Free cash flow
$1.1B
Total assets
$12.9B
Total liabilities
$7.0B
Stockholders' equity
$5.8B
Cash and investments
$1.7B
Total debt
$5.4B

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 28, 2026 Oct 28, 2026
6-K Current report (foreign issuer) Oct 23, 2026 Oct 23, 2026
6-K Current report (foreign issuer) Oct 13, 2026 Oct 13, 2026
6-K Current report (foreign issuer) Oct 7, 2026 Oct 7, 2026
6-K Current report (foreign issuer) Oct 5, 2026 Oct 5, 2026
6-K Current report (foreign issuer) Oct 2, 2026 Oct 2, 2026

All 565 Genmab A/S SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.